Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study
Abstract Background Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing on breast cancer-related MAHA. Methods Main inclusi...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13058-021-01386-y |
id |
doaj-f7239abd3511401b9773a7aef4c9d1ce |
---|---|
record_format |
Article |
spelling |
doaj-f7239abd3511401b9773a7aef4c9d1ce2021-04-02T16:48:01ZengBMCBreast Cancer Research1465-542X2021-01-0123111010.1186/s13058-021-01386-yCharacteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre studyMarion Alhenc-Gelas0Luc Cabel1Frederique Berger2Suzette Delaloge3Jean-Sebastien Frenel4Christelle Levy5Nelly Firmin6Sylvain Ladoire7Isabelle Desmoulins8Pierre-Etienne Heudel9Florence Dalenc10Delphine Loirat11Coraline Dubot12Perrine Vuagnat13Elise Deluche14Meriem Mokdad-Adi15Anne Patsouris16Josselin Annic17Lounes Djerroudi18Marion Lavigne19Jean-Yves Pierga20Paul Coppo21Francois-Clement Bidard22Department of Medical Oncology, Institut CurieDepartment of Medical Oncology, Institut CurieInstitut Curie, Biometry UnitDepartment of Cancer Medicine, Institut Gustave RoussyDepartment of Medical Oncology, Institut de Cancérologie de l’OuestDepartment of Medical Oncology, Centre François BaclesseDepartment of Medical Oncology, Institut du Cancer de Montpellier, Institut de cancérologie de Montpellier INSERM U1194Department of Medical Oncology, Centre Georges-François LeclercDepartment of Medical Oncology, Centre Léon BérardDepartment of Medical Oncology, Centre Léon BérardDepartment of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)Department of Medical Oncology, Institut CurieDepartment of Medical Oncology, Institut CurieDepartment of Medical Oncology, Institut CurieDepartment of Cancer Medicine, Institut Gustave RoussyDepartment of Cancer Medicine, Institut Gustave RoussyDepartment of Medical Oncology, Institut de Cancérologie de l’OuestDepartment of Medical Oncology, Institut de Cancérologie de l’OuestDepartment of Pathology, Institut CurieDepartment of Pathology, Institut CurieDepartment of Medical Oncology, Institut CurieReference Center for Thrombotic Microangiopathies (CNR-MAT), AP-HP.SU, INSERM UMRSDepartment of Medical Oncology, Institut CurieAbstract Background Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing on breast cancer-related MAHA. Methods Main inclusion criteria were known diagnosis of breast cancer, presence of schistocytes and either low haptoglobin or cytopenia and absence of any causes of MAHA other than breast cancer, including gemcitabine- or bevacizumab-based treatment. Patient characteristics, treatments and outcome were retrieved from digital medical records. Results Individual data from 54 patients with breast cancer-related MAHA were obtained from 7 centres. Twenty-three (44%) patients had a breast tumour with lobular features, and most primary tumours were low grade (grade I/II, N = 39, 75%). ER+/HER2−, HER2+ and triple-negative phenotypes accounted for N = 33 (69%), N = 7 (15%) and N = 8 (17%) cases, respectively. All patients had stage IV cancer at the time of MAHA diagnosis. Median overall survival (OS) was 28 days (range 0–1035; Q1:10, Q3:186). Independent prognostic factors for early death (≤ 28 days) were PS > 2 (OR = 7.0 [1.6; 31.8]), elevated bilirubin (OR = 6.9 [1.1; 42.6]), haemoglobin < 8.0 g/dL (OR = 3.7 [0.9; 16.7]) and prothrombin time < 50% (OR = 9.1 [1.2; 50.0]). A score to predict early death displayed a sensitivity of 86% (95% CI [0.67; 0.96]), a specificity of 73% (95% CI [0.52; 0.88]) and an area under the curve of 0.90 (95% CI [0.83; 0.97]). Conclusions Breast cancer-related MAHA appears to be a new feature of invasive lobular breast carcinoma. Prognostic factors and scores may guide clinical decision-making in this serious but not always fatal condition.https://doi.org/10.1186/s13058-021-01386-yMicroangiopathic haemolytic anaemiaBreast cancerSurvivalPrognostic factors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marion Alhenc-Gelas Luc Cabel Frederique Berger Suzette Delaloge Jean-Sebastien Frenel Christelle Levy Nelly Firmin Sylvain Ladoire Isabelle Desmoulins Pierre-Etienne Heudel Florence Dalenc Delphine Loirat Coraline Dubot Perrine Vuagnat Elise Deluche Meriem Mokdad-Adi Anne Patsouris Josselin Annic Lounes Djerroudi Marion Lavigne Jean-Yves Pierga Paul Coppo Francois-Clement Bidard |
spellingShingle |
Marion Alhenc-Gelas Luc Cabel Frederique Berger Suzette Delaloge Jean-Sebastien Frenel Christelle Levy Nelly Firmin Sylvain Ladoire Isabelle Desmoulins Pierre-Etienne Heudel Florence Dalenc Delphine Loirat Coraline Dubot Perrine Vuagnat Elise Deluche Meriem Mokdad-Adi Anne Patsouris Josselin Annic Lounes Djerroudi Marion Lavigne Jean-Yves Pierga Paul Coppo Francois-Clement Bidard Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study Breast Cancer Research Microangiopathic haemolytic anaemia Breast cancer Survival Prognostic factors |
author_facet |
Marion Alhenc-Gelas Luc Cabel Frederique Berger Suzette Delaloge Jean-Sebastien Frenel Christelle Levy Nelly Firmin Sylvain Ladoire Isabelle Desmoulins Pierre-Etienne Heudel Florence Dalenc Delphine Loirat Coraline Dubot Perrine Vuagnat Elise Deluche Meriem Mokdad-Adi Anne Patsouris Josselin Annic Lounes Djerroudi Marion Lavigne Jean-Yves Pierga Paul Coppo Francois-Clement Bidard |
author_sort |
Marion Alhenc-Gelas |
title |
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study |
title_short |
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study |
title_full |
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study |
title_fullStr |
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study |
title_full_unstemmed |
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study |
title_sort |
characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study |
publisher |
BMC |
series |
Breast Cancer Research |
issn |
1465-542X |
publishDate |
2021-01-01 |
description |
Abstract Background Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing on breast cancer-related MAHA. Methods Main inclusion criteria were known diagnosis of breast cancer, presence of schistocytes and either low haptoglobin or cytopenia and absence of any causes of MAHA other than breast cancer, including gemcitabine- or bevacizumab-based treatment. Patient characteristics, treatments and outcome were retrieved from digital medical records. Results Individual data from 54 patients with breast cancer-related MAHA were obtained from 7 centres. Twenty-three (44%) patients had a breast tumour with lobular features, and most primary tumours were low grade (grade I/II, N = 39, 75%). ER+/HER2−, HER2+ and triple-negative phenotypes accounted for N = 33 (69%), N = 7 (15%) and N = 8 (17%) cases, respectively. All patients had stage IV cancer at the time of MAHA diagnosis. Median overall survival (OS) was 28 days (range 0–1035; Q1:10, Q3:186). Independent prognostic factors for early death (≤ 28 days) were PS > 2 (OR = 7.0 [1.6; 31.8]), elevated bilirubin (OR = 6.9 [1.1; 42.6]), haemoglobin < 8.0 g/dL (OR = 3.7 [0.9; 16.7]) and prothrombin time < 50% (OR = 9.1 [1.2; 50.0]). A score to predict early death displayed a sensitivity of 86% (95% CI [0.67; 0.96]), a specificity of 73% (95% CI [0.52; 0.88]) and an area under the curve of 0.90 (95% CI [0.83; 0.97]). Conclusions Breast cancer-related MAHA appears to be a new feature of invasive lobular breast carcinoma. Prognostic factors and scores may guide clinical decision-making in this serious but not always fatal condition. |
topic |
Microangiopathic haemolytic anaemia Breast cancer Survival Prognostic factors |
url |
https://doi.org/10.1186/s13058-021-01386-y |
work_keys_str_mv |
AT marionalhencgelas characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT luccabel characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT frederiqueberger characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT suzettedelaloge characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT jeansebastienfrenel characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT christellelevy characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT nellyfirmin characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT sylvainladoire characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT isabelledesmoulins characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT pierreetienneheudel characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT florencedalenc characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT delphineloirat characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT coralinedubot characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT perrinevuagnat characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT elisedeluche characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT meriemmokdadadi characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT annepatsouris characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT josselinannic characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT lounesdjerroudi characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT marionlavigne characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT jeanyvespierga characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT paulcoppo characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy AT francoisclementbidard characteristicsandoutcomeofbreastcancerrelatedmicroangiopathichaemolyticanaemiaamulticentrestudy |
_version_ |
1721555501928415232 |